Clinical course of inflammatory bowel disease during treatment with interferon for associated chronic active hepatitis
Seven patients with inactive ulcerative colitis and seven patients with Crohn's disease (5 inactive, 2 mildly active) received interferon treatment for associated chronic active hepatitis. Neither relapse (except in one patient) nor worsening of the clinical course of the inflammatory bowel disease was observed during treatment. According to these results chronic active hepatitis associated with inflammatory bowel disease can be treated with interferon without the risk of deteriorating the course of the inflammatory bowel disease.
Available from: Konstantinos D Pantazis
- "Gastrointestinal disorders (especially diarrhea) are observed in a proportion of patients treated with the currently approved combination treatment for chronic hepatitis C (CHC), pegylated-interferon alpha (PEG-IFNa) plus ribavirin (RIB) . Several reports suggest that the presence of inflammatory bowel disease (IBD) is not a contraindication for interferon-alpha-(IFNa-) based treatments  . Furthermore, a randomised placebo-controlled trial of PEG- IFNa in patients with active ulcerative colitis concluded that PEG-IFNa is safe but not effective treatment for these patients . "
Gastroenterology Research and Practice 02/2008; 2008:637517. DOI:10.1155/2008/637517 · 1.75 Impact Factor
Journal of Clinical Gastroenterology 08/1997; 25(1):398-9. DOI:10.1097/00004836-199707000-00027 · 3.50 Impact Factor
The American Journal of Gastroenterology 05/2001; 96(6):1681-1684. DOI:10.1111/j.1572-0241.2001.03859.x · 10.76 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.